Treating chronic viral infection by epigenetic reprogramming of exhausted CD8 T cells

通过对耗尽的 CD8 T 细胞进行表观遗传重编程来治疗慢性病毒感染

基本信息

  • 批准号:
    10242714
  • 负责人:
  • 金额:
    $ 52.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-25 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

During many chronic viral infections, virus-specific CD8 T cells become exhausted as a result of prolonged antigenic and inflammatory stimulation. Exhausted CD8 T cells are characterized by a progressive loss of the ability to produce effector cytokines and kill target cells, poor proliferative capacity, and increased expression of multiple inhibitory receptors. T cell exhaustion was first characterized in the murine model of lymphocytic choriomeningitis virus (LCMV) infection. Considerable effort has been focused on elucidating the mechanisms that regulate T cell exhaustion, with multiple factors and pathways implicated. Blockade of the PD-1:PD-L1 inhibitory pathway early during infection can prevent progression of CD8 T cell exhaustion and, if given at later time points, can partially rescue the function of exhausted CD8 T cells. Recent results show that PD-L1 blockade does not reinvigorate all exhausted CD8 T cells but selectively expands a subset of exhausted CD8 T cells into effectors that function only temporarily, reverting back to the exhausted state. Even when removed from the chronic infection environment, exhausted CD8 T cells are unable to differentiate into functional memory, indicating that the functional defects are molecularly imprinted within exhausted T cells. Our recent work has shown that progressive loss of CD8 T cell functionality during chronic LCMV infection is associated with decreased diacetylated histone H3 (diAcH3) levels globally and at specific loci encoding effector cytokines, indicating a loss of open chromatin structure at these loci. In vitro treatment of exhausted T cells with valproic acid (VPA), a histone deacetylase inhibitor (HDACi), restores diAcH3 levels and effector cytokine production. Remarkably, when adoptively transferred into naïve hosts, VPA-treated “exhausted” CD8 T cells exhibit improved functionality for an extended period of time and differentiate into functional memory T cells with enhanced recall responses. Together, these results show that epigenetics plays a crucial role in regulating T cell exhaustion and may hold the key to reprogramming exhausted T cells into functional effectors capable of clear chronic infection. In this application, we will test 1) if adoptive transfer of exhausted CD8 T cells that have been rescued by in vitro HDACi treatment will work in vivo to clear an established chronic LCMV infection, and 2) if direct treatment of chronically infected mice with HDACi in vivo can rejuvenate exhausted CD8 T cell and allow for viral clearance. We will examine how exhausted T cells are reprogrammed epigenetically and transcriptionally by HDAC inhibition to understand the mechanisms of HDACi in rescuing exhaustion. We will test whether HDACi can reprogram and rescue subsets of exhausted CD8 T cells that fail to respond to PD-L1 blockade. We will examine if combining PD-L1 blockade with epigenetic manipulation synergizes to restore the functionality of all exhausted CD8 T cells and achieve faster viral clearance. Through these studies, we hope to gain a better understanding of the molecular mechanisms underlying T cell exhaustion and to develop an optimal strategy for enhancing immune control and clearance of chronic viral infection.
在许多慢性病毒感染期间,病毒特异性 CD8 T 细胞由于长期感染而耗尽。 抗原和炎症刺激。耗竭的 CD8 T 细胞的特点是逐渐丧失 产生效应细胞因子并杀死靶细胞的能力,增殖能力差,表达增加 多种抑制性受体。 T 细胞耗竭首先在小鼠淋巴细胞模型中得到表征 脉络膜脑膜炎病毒(LCMV)感染。相当多的努力集中在阐明机制上 调节 T 细胞耗竭,涉及多种因素和途径。阻断 PD-1:PD-L1 感染早期的抑制途径可以防止 CD8 T 细胞耗竭的进展,如果稍后给予 时间点,可以部分挽救耗尽的CD8 T细胞的功能。最近的结果表明 PD-L1 封锁不会使所有耗尽的 CD8 T 细胞重新焕发活力,但会选择性地扩增耗尽的 CD8 T 细胞的子集 细胞转变为仅暂时起作用的效应器,恢复到耗尽状态。即使被移除 由于慢性感染环境,耗尽的 CD8 T 细胞无法分化为功能性 T 细胞。 记忆,表明功能缺陷被分子印记在耗尽的 T 细胞内。我们最近的 研究表明,慢性 LCMV 感染期间 CD8 T 细胞功能的逐渐丧失与 全球和特定位点编码效应子的二乙酰化组蛋白 H3 (diAcH3) 水平降低 细胞因子,表明这些位点开放染色质结构的丧失。耗竭 T 细胞的体外治疗 含有组蛋白脱乙酰酶抑制剂 (HDACi) 丙戊酸 (VPA),可恢复 diAcH3 水平和效应细胞因子 生产。值得注意的是,当过继转移到幼稚宿主体内时,经 VPA 处理的 CD8 T 细胞“耗尽” 在较长时间内表现出改进的功能并分化为功能性记忆 T 细胞 具有增强的回忆反应。总之,这些结果表明表观遗传学在调节中起着至关重要的作用。 T 细胞耗竭,可能是将耗竭的 T 细胞重新编程为功能效应器的关键,该效应器能够 明确慢性感染。在此应用中,我们将测试 1) 是否过继转移已耗尽的 CD8 T 细胞 通过体外 HDACi 治疗获救的患者将在体内发挥作用,清除已确定的慢性 LCMV 感染,并且 2) 体内直接用 HDACi 治疗慢性感染小鼠是否可以使耗尽的 CD8 T 细胞恢复活力,并且 允许病毒清除。我们将研究耗尽的 T 细胞如何进行表观遗传重编程, 通过 HDAC 抑制进行转录,以了解 HDACi 拯救疲劳的机制。我们将 测试 HDACi 是否可以重新编程并拯救无法响应 PD-L1 的耗尽 CD8 T 细胞子集 封锁。我们将研究 PD-L1 阻断与表观遗传操作相结合是否可以协同恢复 所有耗尽的 CD8 T 细胞的功能并实现更快的病毒清除。通过这些研究,我们 希望更好地了解 T 细胞耗竭的分子机制并开发 增强免疫控制和清除慢性病毒感染的最佳策略。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Antigen-specific memory Th17 cells promote cross-protection against nontypeable Haemophilus influenzae after mild influenza A virus infection.
  • DOI:
    10.1016/j.mucimm.2023.01.007
  • 发表时间:
    2023-04
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Zhang, Xinyun;Yang, Ying;Chen, ShengSen;Li, Wenchao;Li, Yong;Akerley, Brian J.;Shao, Linyun;Zhang, Wenhong;Shen, Hao;Abt, Michael C.
  • 通讯作者:
    Abt, Michael C.
Next steps in the identification of gene targets for type 1 diabetes.
  • DOI:
    10.1007/s00125-020-05248-8
  • 发表时间:
    2020-11
  • 期刊:
  • 影响因子:
    8.2
  • 作者:
    Grant SFA;Wells AD;Rich SS
  • 通讯作者:
    Rich SS
Immunological consequences of microbiome-based therapeutics.
基于微生物组的治疗剂的免疫学后果。
  • DOI:
    10.3389/fimmu.2022.1046472
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael C. Abt其他文献

Standard mouse diets lead to differences in severity in infectious and non-infectious colitis
标准小鼠饮食导致感染性和非感染性结肠炎严重程度的差异
  • DOI:
    10.1128/mbio.03302-24
  • 发表时间:
    2025-02-25
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Joshua E. Denny;Julia N. Flores;Nontokozo V. Mdluli;Michael C. Abt
  • 通讯作者:
    Michael C. Abt
Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation
造血干细胞移植后的单核细胞重建和肠道菌群组成
  • DOI:
    10.1101/777268
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. Morjaria;Allen W. Zhang;Sohn G. Kim;J. Peled;Simone Becattini;E. Littmann;E. Pamer;M. Perales;Michael C. Abt
  • 通讯作者:
    Michael C. Abt
Antigen-specific memory Th17 cells promote cross-protection against nontypeable emHaemophilus influenzae/em after mild influenza A virus infection
抗原特异性记忆 Th17 细胞促进轻度甲型流感病毒感染后对非分型流感嗜血杆菌的交叉保护
  • DOI:
    10.1016/j.mucimm.2023.01.007
  • 发表时间:
    2023-04-01
  • 期刊:
  • 影响因子:
    7.600
  • 作者:
    Xinyun Zhang;Ying Yang;ShengSen Chen;Wenchao Li;Yong Li;Brian J. Akerley;Linyun Shao;Wenhong Zhang;Hao Shen;Michael C. Abt
  • 通讯作者:
    Michael C. Abt
Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to emClostridioides difficile/em infection
产生白细胞介素-22 的先天淋巴细胞的治疗性激活增强了宿主对艰难梭菌感染的防御能力。
  • DOI:
    10.1016/j.celrep.2025.115438
  • 发表时间:
    2025-04-22
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Kevin S. Mears;Joshua E. Denny;Jeffrey R. Maslanka;Nontokozo V. Mdluli;Ellie N. Hulit;Rina Matsuda;Emma E. Furth;Charlie G. Buffie;Michael C. Abt
  • 通讯作者:
    Michael C. Abt

Michael C. Abt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael C. Abt', 18)}}的其他基金

Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infection
项目 3:定义影响艰难梭菌感染的适应性免疫相互作用
  • 批准号:
    10625579
  • 财政年份:
    2023
  • 资助金额:
    $ 52.96万
  • 项目类别:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
研究粪便微生物组移植治疗艰难梭菌期间免疫-微生物组的相互作用
  • 批准号:
    10549862
  • 财政年份:
    2021
  • 资助金额:
    $ 52.96万
  • 项目类别:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
研究粪便微生物组移植治疗艰难梭菌期间免疫-微生物组的相互作用
  • 批准号:
    10343845
  • 财政年份:
    2021
  • 资助金额:
    $ 52.96万
  • 项目类别:
Immune regulation of the transcriptional and spatial profile of Clostridioides difficile
艰难梭菌转录和空间谱的免疫调节
  • 批准号:
    10288376
  • 财政年份:
    2021
  • 资助金额:
    $ 52.96万
  • 项目类别:
Immune regulation of the transcriptional and spatial profile of Clostridioides difficile
艰难梭菌转录和空间谱的免疫调节
  • 批准号:
    10448396
  • 财政年份:
    2021
  • 资助金额:
    $ 52.96万
  • 项目类别:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
研究粪便微生物组移植治疗艰难梭菌期间免疫-微生物组的相互作用
  • 批准号:
    10185169
  • 财政年份:
    2021
  • 资助金额:
    $ 52.96万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 52.96万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 52.96万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 52.96万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 52.96万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 52.96万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 52.96万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 52.96万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 52.96万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 52.96万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 52.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了